Home Members Tools Credit Cards
   

RIGL Stock Quote and Technical Analysis

Portfolios Markets Resources
  Symbol List
Rigel Pharmaceuticals, Inc. (RIGL)
▲ 2.07 (+0.03) 1.47%
Open: 2.08
High: 2.10
Low: 1.98
Afterhours: N/A - N/A
Volume: 353266
11/21/2014 4:00pm
 
Interactive Chart
EPS: -0.976 (Current Year Estimated: -1.07)
Dividend: N/A
P/E: N/A

Technicals:
52 Week Range: 1.56 - 5.00
50 Day Moving Average: 1.8606
200 Day Moving Average: 2.7403
Pivot Point (Next Trading Session): 2.05

Login or signup free to Add "RIGL" to your portfolio

Resources:

News:


RIGEL PHARMACEUTICALS INC Financials
Fri, 14 Nov 2014 18:04:38 GMT


10-Q for Rigel Pharmaceuticals, Inc.
Fri, 07 Nov 2014 00:08:37 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Tue, 04 Nov 2014 21:20:12 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Tue, 04 Nov 2014 18:47:09 GMT


Rigel posts 3Q loss
Tue, 04 Nov 2014 14:37:01 GMT


Rigel posts 3Q loss
Tue, 04 Nov 2014 14:37:01 GMT


Rigel Announces Third Quarter 2014 Financial Results
Tue, 04 Nov 2014 13:20:38 GMT
[at noodls] - News Release SOUTH SAN FRANCISCO, Calif., Nov. 4, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30, ...

Rigel Announces Third Quarter 2014 Financial Results
Tue, 04 Nov 2014 12:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., Nov. 4, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30, 2014. For ...

Rigel's R348 Fails in Phase II Study, Shares Down 13.6%
Thu, 14 Aug 2014 18:30:03 GMT


Why Rigel Pharmaceuticals (RIGL) Stock Is Declining Today
Wed, 13 Aug 2014 19:37:00 GMT


Rigel eye drug fails mid-stage study, shares fall
Wed, 13 Aug 2014 14:48:52 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Wed, 13 Aug 2014 12:00:35 GMT


Rigel experimental eye drug fails mid-stage study
Wed, 13 Aug 2014 11:44:34 GMT


R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study
Wed, 13 Aug 2014 11:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., Aug. 13, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease. The endpoints were measured by changes in corneal fluorescein staining, conjunctival staining, tear production and dry eye symptom scores from baseline over 12 weeks of treatment versus placebo. No significant adverse events were reported in the trial. Rigel has decided not to initiate any new studies of R348 for this indication, but is continuing its Phase 2 study of dry eye in patients with graft versus host disease (GvHD). The Company is focusing its resources on advanced clinical studies of fostamatinib in two indications. The fostamatinib programs include a recently initiated Phase 3 study in patients with immune thrombocytopenic purpura (ITP) and its planned Phase 2 study in patients with IgA Nephropathy (IgAN), an autoimmune disease of the kidneys, in Q4 2014. For more information on fostamatinib in IgAN, please visit: http://www.rigel.com/rigel/IgAN.

RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Tue, 05 Aug 2014 20:05:33 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Tue, 05 Aug 2014 17:20:59 GMT


Rigel Announces Second Quarter 2014 Financial Results
Tue, 05 Aug 2014 11:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., Aug. 5, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2014. For the second ...

Rigel Pharmaceuticals Starts Fostamatinib Late Stage Program
Thu, 17 Jul 2014 19:45:06 GMT


Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
Wed, 16 Jul 2014 12:35:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., July 16, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura). The focus of these clinical studies is to evaluate the potential of fostamatinib to increase the platelet counts of patients with chronic ITP. Fostamatinib may provide a novel therapeutic for the underlying cause of this autoimmune disease of the blood. "Based on our extensive clinical experience with this product candidate, which includes more than 4,500 patient-years of data, we hope to demonstrate that fostamatinib can provide a new treatment option for patients with chronic ITP," said James M. Gower, chairman and chief executive officer of Rigel.

Rigel Pharmaceuticals initiates Phase 3 studies of fostamatinib in ITP
Wed, 16 Jul 2014 11:31:59 GMT


All Company News is Powered by Yahoo! Finance

 

 

 

Credit Cards | Finance Social Network | Credit Card Reviews | Markets
About Us | FG on the Web | Sitemap | Privacy | Terms | Contact


Copyright © 2014 Finance Globe. All rights reserved.